Foreword
Every tissue has some degree of mesenchymal cell contribution whether it be rare as with perivascular cells in the brain or abundant as in bone. In mesenchymal tissues like bone, there is a great deal known about lineage relationships and function, but the same cannot be said to be true for most organs where the epithelial components have largely been the focus of research. The ubiquity of mesenchymal cells in all organs may be one reason why they have generally been understudied as they are regarded as simply a part of supportive stroma.
However, the role of mesenchymal cells in organ formation is well recognized as central to development, providing an interplay with other cell types in guiding patterning and morphology. In adult tissues, they have been most evident as functional participants in wounding but are highly likely to play important roles in the maintenance of the tissue as well. The setting where this is increasingly appreciated is the bone marrow. A number of studies have now indicated a primary role for mesenchymal cells in regulating the hematopoietic stem and progenitor cells. These studies have further indicated that mesenchymal cells are highly diverse even within a given tissue. For example, in the bone marrow, it is evident that cells expressing different marker genes like nestin, leptin receptor, or osterix are not entirely overlapping and express different levels of other proteins implicated in stem cell function. Further, at least some of the cells appear to turn over rapidly and be replenished by a resident stem cell pool. And the function of the mesenchymal cells seems to be important in the integrity of the tissue. Several models of altered mesenchymal cell function have resulted in changes in hematologic function indicating the clear dependence on intact interplay between mesenchymal and parenchymal cell types for the tissue to function normally. Collectively, these kinds of studies are raising awareness of the complexity, dynamism, and centrality of endogenous mesenchymal cells for tissue health. They have to some extent trailed the many studies of mesenchymal cells cultured ex vivo and used therapeutically, and yet, they support and deepen the rationale for such studies.
The behavior of endogenous mesenchymal cells in tissues includes a highly unusual ability to fundamentally change cell state. In development, certain mesenchymal cells such as those of the developing kidney are known to transition to acquire epithelial features. Mesenchymal to epithelial transition is well accepted in the normal course of tissue formation, particularly in forming the nephron. Similarly, mesenchymal cell characteristics are known to be acquired by some epithelial cells in development such as in gastrulation but are best characterized in pathologic conditions, speci fi cally in cancer. The epithelial to mesenchymal transition (EMT) is regarded as a signature pathologic process of malignancy that is now being associated with cells acquiring more stem cell-like features and to be driven by particular genes like Twist, Snail, and Slug. This process is thought to re fl ect a potentially more metastasis-prone cell phenotype. It is striking that cells can acquire mesenchymal features with very little evidence that alternative cell states can be achieved. Transition to other somatic cell types is simply not seen. This does raise the issue of whether the mesenchymal cell state is not rigidly constrained and that cells can achieve it perhaps with less epigenetic precision than required for other cell types.
The ability of cells to acquire mesenchymal-like features may be part of the reason why virtually every organ appears to have so-called mesenchymal stem cells. These cells are generally de fi ned by their functions in vitro, the ability to form three lineages, bone, cartilage, and adipose cell types. The cells from different tissues are likely to be distinctive, yet once cultured they have a highly similar phenotype. It is not clear if this is re fl ective of a uniform phenotype in vivo or even of a uniform gene expression signature after in vitro culture. However, whether such distinctions exist may be of interest but may not have signi fi cant functional consequences. The cultured cell populations may very well share critical features selected for by the process of cell culture.
The cultured mesenchymal cells with a shared tri-lineage differentiation potential also appear to have unexpected immunologic features. They are capable of altering the immunologic reactivity of the host upon adoptive transfer and may have immune-modulating properties in residence. While there is skepticism regarding this issue, it should be remembered that tissue resident immunologic functions of dendritic cells and endothelial cells were also regarded skeptically when fi rst proposed and it may well be that mesenchymal cells represent the next generation of such cell populations discovered to play central roles. The putative immunologic effects of transferred mesenchymal cells are not a global immune suppression. There is no evidence of a predisposition to infection as occurs with most immunosuppressive drugs. The immunologic alteration may be more subtle and perhaps more of a reset of a hyperreactive immunologic state as is present in most of the conditions where the cells have been tested. The mechanistic basis by which the cells can induce an effect that apparently lasts longer than the persistence of the infused mesenchymal cells has many hypotheses. Most of these are related to elaboration of proteins exerting a paracrine effect. Some of these effects may also alter activities like hematopoietic stem cell engraftment.
The volume expertly edited here by Drs. Peiman Hematti and Armand Keating represents an assembly of reviews and perspectives from leading investigators in the fi eld. It addresses controversies of the fi eld head-on and covers topics from underlying biology to clinical testing in multiple settings to the all important regulatory considerations in preparing such cells for use in patients. It is an extremely impor-tant, timely, and thoughtful addition to a rapidly changing fi eld and will be a resource for those entering or active in the study of these intriguing cells. This cell type is likely to become a mainstay in the medical armamentarium. We are still in the early days of de fi ning where and how they can be optimally active. A guiding resource such as this volume will help move the process forward. 
Preface
Alexander Friedenstein is rightfully credited with discovery of what we now know as mesenchymal stromal cells (MSCs) more than four decades ago. Friedenstein's seminal work showed that bone marrow, in addition to hematopoietic stem cells, contained a population of cells capable of generating hematopoietic supportive stroma, bone, fat, and cartilage. In the last decade, work in the fi eld of MSCs has exploded, and now these cells have become the most commonly used in regenerative medicine only after hematopoietic stem/progenitor cells. The rapidly increasing number of clinical trials in a broad range of applications attests to considerable clinical potential. Applications span from their use as supportive cells for the ex vivo expansion of cord blood cells to treatment of localized defects, wounds and pathologies, and for systemic diseases with different pathophysiology. MSCs have been investigated in small-and large-scale clinical trials for acute and chronic graftversus-host disease, myocardial infarction, diabetes, chronic obstructive pulmonary disease, systemic lupus erythematosus, systemic sclerosis, lower limb ischemia, stroke, multiple sclerosis, amyotrophic lateral sclerosis, kidney transplantation, nonhealing cutaneous wounds, bone and cartilage defects, and inborn errors of metabolism. Despite the rapid advances into the clinic, an assessment of the therapeutic ef fi cacy of MSCs remains a challenge. It is therefore incumbent on us to carefully evaluate and reappraise the fi eld. This book attempts to address these issues and consists of 38 chapters that comprise a range of topics from basic biology of MSCs to their clinical application. It also addresses the controversies surrounding their mechanisms of action.
The fi rst part of this book discusses the latest advances in our understanding of the biological properties of MSCs in vitro and in vivo. This part covers the basic science involved in immunophenotypic and functional characterization of MSCs, technological innovations of their in vivo investigation, and a new understanding of potential mechanisms of action. Also, views and controversies are discussed in the context of a more recent understanding of cellular and molecular mechanisms of action of MSCs. The second part of the book is a comprehensive resource to readers interested in the translational and regulatory aspects of MSCs as cell therapy. Our goal here is to fi ll the gaps between "bench" and "bedside" and help connect our understanding of MSC biology with the requirements of clinical investigation. These chapters provide a guide on how to bring MSCs from basic research laboratories to the clinic. The third part of the book offers an extensive coverage of the clinical use of MSCs involving almost all human tissues and organs that have served as targets for this treatment. These chapters explore the rationale, design, safety, and ef fi cacy of published and ongoing clinical trials.
The authors represent an international group of basic, translational, and clinical investigators from almost all sub-subspecialties of medicine as well as experts in the regulatory aspects of cellular therapy. Moreover, all the contributors have been directly involved in the various aspects of MSC research. We hope that this book will provide a benchmark for the most exciting developments in the investigation and clinical use of mesenchymal stromal cells. 
